N-(3-nitropyridin-4-yl)cyclopropanecarboxamide | 1428065-95-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(3-nitropyridin-4-yl)cyclopropanecarboxamide
• 英文别名: N-(3-Nitro-4-pyridinyl)cyclopropanecarboxamide
• CAS: 1428065-95-5
• 化学式: C₉H₉N₃O₃
• 分子量: 207.189
• InChiKey: HTQXOHSLTBARFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  87.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氨基-3-硝基吡啶 、 环丙基甲酰氯 在 乙酸乙酯 、 水 、 Brine 、 magnesium sulfate 作用下， 以 吡啶 为溶剂， 反应 3.0h， 以to afford N-(3-nitropyridin-4-yl)cyclopropanecarboxamide (LXXVII) as a light yellow solid (740 mg, 3.57 mmol, 99.5% yield)的产率得到N-(3-nitropyridin-4-yl)cyclopropanecarboxamide
  参考文献：
  名称：

  5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

  摘要：

  本发明揭示了用于治疗各种疾病和病理的吲唑化合物。更具体地，本发明涉及使用吲唑化合物或其类似物治疗以Wnt通路信号激活为特征的紊乱（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺病、纤维性疾病、软骨（软骨）缺陷和骨关节炎），调节由Wnt通路信号介导的细胞事件，以及与DYRK1A过度表达相关的神经系统状况/紊乱/疾病。

  公开号：

  US20150266825A1

文献信息

• [EN] INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS<br/>[FR] INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION PAR WNT/Beta-CATÉNINE
  申请人：SAMUMED LLC

  公开号：WO2013040215A1

  公开（公告）日：2013-03-21

  lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本文披露了用于治疗各种疾病和病理的吲唑-3-羧酰胺化合物。更具体地，本文涉及使用吲唑-3-羧酰胺化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或Wnt信号组分之一或多个的突变或失调而引起的遗传疾病和神经系统疾病/紊乱/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• [EN] METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS<br/>[FR] PROCÉDÉS D'UTILISATION D'INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
  申请人：SAMUMED LLC

  公开号：WO2018075858A1

  公开（公告）日：2018-04-26

  This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

  本公开涉及使用一种或多种吲唑-3-羧酰胺化合物或其盐或类似物，用于治疗独立选择自包括肌腱病、皮炎、牛皮癣、硬皮病、鱼鳞病、雷诺综合征和达里尔病的一种或多种疾病或症状；和/或促进伤口愈合。方法包括向受试者（例如，需要者）施用如本文中任何地方所述的一种或多种吲唑-3-羧酰胺化合物或其盐或类似物的治疗有效量。
• INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS
  申请人：Samumed, LLC

  公开号：US20140045815A1

  公开（公告）日：2014-02-13

  Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本发明揭示了用于治疗各种疾病和病理的吲唑并[3,2-c]吡唑-3-羧酰胺化合物。更具体地，本发明涉及使用吲唑并[3,2-c]吡唑-3-羧酰胺化合物或其类似物，治疗由Wnt通路信号激活引起的疾病（例如癌症，异常细胞增殖，血管生成和骨关节炎），调节由Wnt通路信号介导的细胞事件，以及由于Wnt通路和/或Wnt信号组分之一或多个的突变或失调引起的遗传疾病和神经系统疾病/疾病/病症。还提供了治疗Wnt相关疾病状态的方法。
• INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS
  申请人：Hood John

  公开号：US20130079329A1

  公开（公告）日：2013-03-28

  Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本发明公开了用于治疗各种疾病和病理的吲唑并[3,2-c]异噁唑-3-羧酰胺化合物。更具体地，本发明涉及使用吲唑并[3,2-c]异噁唑-3-羧酰胺化合物或其类似物，治疗由Wnt途径信号激活引起的疾病（例如癌症、异常细胞增殖、血管生成和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由Wnt途径和/或一个或多个Wnt信号传导组分的突变或失调引起的遗传疾病和神经系统疾病/障碍/疾病的方法。还提供了治疗Wnt相关疾病状态的方法。
• Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
  申请人：Samumed, LLC

  公开号：US10464924B2

  公开（公告）日：2019-11-05

  Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本发明公开了用于治疗各种疾病和病理的吲唑-3-甲酰胺化合物。更具体地说，本发明涉及一种吲唑-3-甲酰胺化合物或其类似物在治疗以 Wnt 通路信号激活为特征的疾病（如癌症、异常细胞增殖、血管生成和骨关节炎）、调节由 Wnt 通路信号介导的细胞事件以及由于 Wnt 通路和/或一种或多种 Wnt 信号成分的突变或失调引起的遗传疾病和神经系统病症/失调/疾病中的用途。此外，还提供了治疗 Wnt 相关疾病状态的方法。